Read Our News And Press Releases

Read our news and press releases

As a business striving for growth, Halberd is rapidly changing. This means that we have many stories to tell, we like to share them with you.

Aug 22 2023

Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)

By Admin|2023-08-21T18:31:47-04:00August 22nd, 2023|Featured, Investor News, News, Press Releases|0 Comments

Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product Jackson Center, PA August 22, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model ...

May 31 2023

Halberd CEO Mid-Quarter Update

By Admin|2023-05-31T05:53:16-04:00May 31st, 2023|Investor News, News, Press Releases, Uncategorized, Update Letter|0 Comments

Jackson Center, PA May 31, 2023 – Halberd Corporation (OTC-PINK: "HALB”) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring the public up to date on a few of the most significant efforts. Mississippi State University (MSU) has completed the impacts and sample collection for ...

May 23 2023

Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete

By Admin|2023-05-22T20:43:29-04:00May 23rd, 2023|Featured, Investor News, Press Releases|0 Comments

MSU is ahead of schedule and continues testing program Jackson Center, PA May 23, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd's groundbreaking patent-pending nasal spray. The nasal spray is designed to eliminate ...

May 9 2023

Halberd Pre-Clinical Test Protocol Approved

By Admin|2023-05-08T18:54:10-04:00May 9th, 2023|Investor News, News, Press Releases|0 Comments

Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month End Jackson Center, PA May 9, 2023 – Halberd Corporation (OTC-PINK: "HALB”) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering ...

May 2 2023

Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma

By Admin|2023-05-01T20:26:07-04:00May 2nd, 2023|Investor News, Medical, News, Press Releases|0 Comments

Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process Jackson Center, PA May 2, 2023 – Halberd Corporation (OTC-PINK: "HALB”) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of ...

Apr 25 2023

Halberd Corporation 1Q23 CEO Letter

By Admin|2023-04-24T20:53:26-04:00April 25th, 2023|Investor News, News, Press Releases, Update Letter|0 Comments

Jackson Center, PA, April 25, 2023 -- Halberd Corporation (OTC: HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments. 1st QUARTER 2023 ACHIEVEMENTS Halberd researchers received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) and deadly fungi for testing. Halberd’s laser eradication application ...

Apr 17 2023

ICYMI: Halberd and YSU Interviewed on CBS Affiliate WKBN 5pm News as Research Advances

By Admin|2023-04-16T18:54:51-04:00April 17th, 2023|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, April 17, 2023 – Halberd Corporation’s (OTC PINK:HALB) successful patent protected research being conducted at Youngstown State University (YSU) on antibiotic resistant bacteria and deadly Candida auris was recently featured in a news segment on Youngstown, OH CBS News affiliate television station, WKBN. Professors and student scholar lab assistants are conducting this ...

Mar 30 2023

Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma

By Admin|2023-03-29T19:43:38-04:00March 30th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA March 30, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU. The testing will focus on Halberd’s patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining ...

Mar 21 2023

Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University

By Admin|2023-03-21T18:30:21-04:00March 21st, 2023|Investor News, Medical, News, Press Releases, Uncategorized|0 Comments

Jackson Center, PA, March 21, 2023 – Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC. Using Halberd’s patented extracorporeal ...

Mar 14 2023

Halberd & Centers for Disease Control to Meet Regarding Eradication of Antibiotic Resistant Pathogens

By Admin|2023-03-14T05:42:44-04:00March 14th, 2023|Featured, Investor News, Medical, Press Releases|0 Comments

Halberd’s patented process demonstrates eradication of multiple strains of antibiotic resistant bacteria and fungi in under 10 minutes. Jackson Center, PA, March 14, 2023 – Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd’s incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli ...

Previous 123 Next